CN102816114B - 一种HMG-CoA还原酶抑制剂的制备方法 - Google Patents
一种HMG-CoA还原酶抑制剂的制备方法 Download PDFInfo
- Publication number
- CN102816114B CN102816114B CN201110153203.0A CN201110153203A CN102816114B CN 102816114 B CN102816114 B CN 102816114B CN 201110153203 A CN201110153203 A CN 201110153203A CN 102816114 B CN102816114 B CN 102816114B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- alkali
- mol ratio
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 230000008878 coupling Effects 0.000 claims abstract description 5
- 238000010168 coupling process Methods 0.000 claims abstract description 5
- 238000005859 coupling reaction Methods 0.000 claims abstract description 5
- 125000006239 protecting group Chemical group 0.000 claims abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003513 alkali Substances 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 13
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 150000002596 lactones Chemical class 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- -1 amido lithium Chemical compound 0.000 claims description 4
- 238000005906 dihydroxylation reaction Methods 0.000 claims description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims description 4
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 2
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 claims description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000006340 racemization Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000007142 ring opening reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000002585 base Substances 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 150000002576 ketones Chemical class 0.000 description 7
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- MSHKEMUMXTZIIT-MCBHFWOFSA-N ethyl (e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CCOC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C(C)C)N=C(N(C)S(C)(=O)=O)N=C1C1=CC=C(F)C=C1 MSHKEMUMXTZIIT-MCBHFWOFSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 4
- 229960002797 pitavastatin Drugs 0.000 description 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 2
- 229960003296 pitavastatin calcium Drugs 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-M (3R,5S)-fluvastatin(1-) Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-M 0.000 description 1
- GGZHVNZHFYCSEV-UHFFFAOYSA-N 1-Phenyl-5-mercaptotetrazole Chemical class SC1=NN=NN1C1=CC=CC=C1 GGZHVNZHFYCSEV-UHFFFAOYSA-N 0.000 description 1
- CVULGJIRGZVJHQ-UHFFFAOYSA-N CCc1nc(cccc2)c2[s]1 Chemical compound CCc1nc(cccc2)c2[s]1 CVULGJIRGZVJHQ-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@](C[C@@](N=C*)O)CC(O)=O Chemical compound C[C@](C[C@@](N=C*)O)CC(O)=O 0.000 description 1
- PJQIBTFOXWGAEN-UHFFFAOYSA-N Cc1nc(cccc2)c2[n]1C Chemical compound Cc1nc(cccc2)c2[n]1C PJQIBTFOXWGAEN-UHFFFAOYSA-N 0.000 description 1
- QYSASSWEUXOZEQ-UHFFFAOYSA-N Cc1nnn[n]1-c1ccccc1 Chemical compound Cc1nnn[n]1-c1ccccc1 QYSASSWEUXOZEQ-UHFFFAOYSA-N 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical class FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110153203.0A CN102816114B (zh) | 2011-06-09 | 2011-06-09 | 一种HMG-CoA还原酶抑制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110153203.0A CN102816114B (zh) | 2011-06-09 | 2011-06-09 | 一种HMG-CoA还原酶抑制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102816114A CN102816114A (zh) | 2012-12-12 |
CN102816114B true CN102816114B (zh) | 2014-01-29 |
Family
ID=47300610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110153203.0A Active CN102816114B (zh) | 2011-06-09 | 2011-06-09 | 一种HMG-CoA还原酶抑制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102816114B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4783998B2 (ja) * | 2001-05-15 | 2011-09-28 | 宇部興産株式会社 | (3r,5s)−7−置換−3,5−ジヒドロキシヘプト−6−エン酸の製法 |
KR100511533B1 (ko) * | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
US8455640B2 (en) * | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
-
2011
- 2011-06-09 CN CN201110153203.0A patent/CN102816114B/zh active Active
Non-Patent Citations (4)
Title |
---|
"A NOVEL DIASTEREOSELECTIVE SYNTHESIS OF THE LACTONE MOIETY OF COMPACTIN";Kapa Prasad et al.;《Tetrahedron Letters》;19841231;第25卷(第23期);第2435-2438页 * |
"HMG-CoA还原酶抑制剂中间体合成新工艺";王文金 等;《有机化学》;20081231;第28卷(第4期);第663-666页 * |
Kapa Prasad et al.."A NOVEL DIASTEREOSELECTIVE SYNTHESIS OF THE LACTONE MOIETY OF COMPACTIN".《Tetrahedron Letters》.1984,第25卷(第23期),第2435-2438页. |
王文金 等."HMG-CoA还原酶抑制剂中间体合成新工艺".《有机化学》.2008,第28卷(第4期),第663-666页. |
Also Published As
Publication number | Publication date |
---|---|
CN102816114A (zh) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105330609B (zh) | 一种制备lcz696的方法 | |
EP2602250B1 (en) | Method for preparing rosuvastatin calcium intermediate | |
CN101486706A (zh) | 一种奥美拉唑钠化合物及其合成方法 | |
CN107311861B (zh) | 一种4-甲氧基乙酰乙酸乙酯及其合成方法 | |
CN104860872A (zh) | 一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法 | |
CN104610164A (zh) | 2-(2-正丁基-4-羟基-6-甲基-嘧啶-5-基)-n,n-二甲基乙酰胺的新制备方法 | |
CN102816114B (zh) | 一种HMG-CoA还原酶抑制剂的制备方法 | |
CN102653523A (zh) | 一种匹伐他汀钙重结晶制取方法 | |
CN104744378A (zh) | 一种(e)-3-[4-(4-氟苯基)-6-异丙基-2-(n-甲基-n-甲磺酰胺基)嘧啶-5-基]丙烯醛的合成方法 | |
CN103408487B (zh) | 一种吉莫斯特的精制方法 | |
JPWO2015097850A1 (ja) | 2−アミノニコチン酸ベンジルエステル誘導体の製造方法 | |
CN100381430C (zh) | 取代的烷基胺或其盐的生产方法 | |
CN108530416B (zh) | 一种瑞舒伐他汀中间体的制备方法 | |
JPWO2014051077A1 (ja) | 高純度の含窒素複素環化合物の製造方法 | |
CN102906064A (zh) | 光学纯度得以提高了的(1r,2s)-1-氨基-2-乙烯基环丙烷羧酸酯的制造方法 | |
EP2598485B1 (en) | Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same | |
CN114957134A (zh) | 一种制备嘧菌酯及其中间体的方法 | |
CN106432057A (zh) | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 | |
WO2015012271A1 (ja) | 複素環化合物の製造方法 | |
CN108658931A (zh) | 一种雷替曲塞关键中间体的制备方法 | |
CN102816152A (zh) | 一种瑞苏伐他汀中间体的制备方法 | |
WO2021109883A1 (zh) | 用于制备奥贝胆酸的方法 | |
CN106957259A (zh) | 一种3,5-二溴吡啶的合成方法 | |
CN105622566A (zh) | 一种3,5-二取代羟基-6-取代己酸酯衍生物的制备方法 | |
KR101095706B1 (ko) | 몬테루카스트산 또는 그 나트륨염의 신규한 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121212 Assignee: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Assignor: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Contract record no.: 2014330000383 Denomination of invention: Preparation method of HMG-CoA reductase inhibitor Granted publication date: 20140129 License type: Common License Record date: 20141010 Application publication date: 20121212 Assignee: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Assignor: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Contract record no.: 2014330000382 Denomination of invention: Preparation method of HMG-CoA reductase inhibitor Granted publication date: 20140129 License type: Common License Record date: 20141010 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGYU JINGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI JINGXIN BIOLOGICAL MEDICAL CO., LTD. Effective date: 20150527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201210 PUDONG NEW AREA, SHANGHAI TO: 312369 HANGZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150527 Address after: 312369, No. three, No. 31, Shangyu economic and Technological Development Zone, Hangzhou Bay, Zhejiang Patentee after: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Address before: Shanghai city 201210 libing road Pudong New Area Zhangjiang hi tech Park No. 306 Patentee before: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 31 Weisan Road, Shangyu Economic and Technological Development Zone, Hangzhou Bay, Zhejiang Province, China, 312369 Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Country or region after: China Address before: 31 Weisan Road, Shangyu Economic and Technological Development Zone, Hangzhou Bay, Zhejiang Province, China, 312369 Patentee before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |